Drug news
Actelion acquires rights to Xiaflex/Xiapex from Auxilium Pharma
Actelion will acquire from Auxilium Pharma exclusive rights to commercialise Xiaflex (collagenase Clostridium histolyticum) as a treatment for two rare progressive collagen deposit conditions, Dupuytren�s contracture and Peyronie�s disease, in Canada, Australia, Brazil and Mexico.Xiaflex has already been approved in the US and the EU to treat Dupuytren�s contracture, a fibroproliferative disease in which abnormal collage deposits result in nodules and rope-like cords in the hand, and it is under regulatory review in Canada. Development work on the Dupuytren�s indication in Japan is underway.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
2 mins